Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-Based Atezolizumab Dosing in Cancer
NCT06066138Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in alveolar soft part sarcoma (ASPS), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and 2 more, sponsored by National Cancer Institute. Primary endpoint: Feasibility of reducing drug exposure while maintaining plasma drug concentration at 16 weeks. Started Nov 2025; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
alveolar soft part sarcoma (ASPS)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)hepatocellular carcinoma (HCC)melanoma
Beyond the preview
Go deeper on NCT06066138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06066138.